ALNY

Alnylam Pharmaceuticals, Inc.

Healthcare · $34.5B market cap

We can't put a fair value on ALNY right now. It has fewer than 5 profitable years and uneven cash flow, not enough history to project from yet.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?

Equity per share growth1.5% a year✗

Sales growth47.2% a year✓

Free cash flow growth1.6% a year✗

Return on invested capital-0.1%✗

Follow ALNY

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds ALNY. Who we track

Dodge & Cox Funds

Dodge & Cox Funds · as of Q2 2026

$588.6M

1,955,393 shares

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works

Verdict

Business quality

Superinvestors

About Alnylam Pharmaceuticals, Inc.